☆ 4.4 Article

Children's Oncology Group's 2023 blueprint for research: Pharmacy

PEDIATRIC BLOOD & CANCER (2023)

Related references

Note: Only part of the references are listed.

Article Pharmacology & Pharmacy

Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype

Roseann S. Gammal et al.

Summary: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with the development of acute hemolytic anemia in the presence of oxidative stress. This guideline provides information on using G6PD genotype for diagnosing G6PD deficiency and categorizes medications based on their risk level in individuals with G6PD deficiency. High-risk medications should be avoided, medium-risk medications should be used with caution, and low-risk medications can be used without considering the G6PD phenotype.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Add to Collection

Article Oncology

Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the children's oncology group

Heidi Russell et al.

Summary: Two similar chemotherapy regimens were compared for rhabdomyosarcoma, showing similar tumor outcomes but significant cost differences, influenced by pharmaceutical pricing and location of treatment.

CANCER (2022)

Add to Collection

Article Biotechnology & Applied Microbiology

Incorporating G6PD genotyping to identify patients with G6PD deficiency

Sarah A. Morris et al.

Summary: G6PD deficiency is a common enzyme disorder associated with hemolytic anemia. Clinical G6PD genotyping and activity testing are two commonly used methods that can be used together to determine the G6PD phenotype more accurately.

PHARMACOGENETICS AND GENOMICS (2022)

Add to Collection

Article Oncology

Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621

Maureen M. O'Brien et al.

Summary: The study aims to evaluate the efficacy and safety of inotuzumab ozogamicin in pediatric and adolescent patients with relapsed or refractory B-cell acute lymphoblastic leukemia. The results show that inotuzumab ozogamicin is effective and well tolerated in CD22-positive B-ALL patients. Side effects include sinusoidal obstruction syndrome and cytopenias. Partial CD22 expression and lower CD22 site density are associated with decreased response to inotuzumab ozogamicin.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Stability of extemporaneously compounded temozolomide 10 mg/mL suspensions in Oral Mix SF® in glass and plastic bottles and plastic syringes

Karen Lingertat-Walsh et al.

Summary: The study evaluated the stability of temozolomide oral suspension in different container types and storage temperatures. It was found that temperature had an impact on the concentration changes, while container type and formulation did not. The recommended beyond-use-date for temozolomide 10 mg/mL suspensions is 30 days when stored at 4 degrees C.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2021)

Add to Collection

Article Oncology

Blinatumomab use in pediatric ALL: Taking a BiTE out of preparation, administration and toxicity challenges

Melanie B. Bernhardt et al.

Summary: Blinatumomab is a bispecific T-cell engager monoclonal antibody approved by the FDA for the treatment of specific types of lymphocytic leukemia. Despite its impressive efficacy, challenges exist in its preparation, administration, toxicity monitoring, and medication error prevention.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia A Randomized Clinical Trial

Patrick A. Brown et al.

Summary: In children, adolescents, and young adults with high- and intermediate-risk first relapse of B-ALL, postreinduction treatment with blinatumomab compared with chemotherapy, followed by transplant, did not result in a statistically significant difference in disease-free survival. However, study interpretation is limited by early termination with possible underpowering for the primary end point.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Oncology

Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with event-free survival in intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group

Navin Pinto et al.

Summary: In patients with newly diagnosed intermediate-risk rhabdomyosarcoma, the relationship between genetic polymorphisms and cyclophosphamide treatment efficacy is complex, and a pharmacogenomic approach to personalize therapy based on drug metabolism genes is not feasible. Alternative personalized therapy methods should be explored.

PEDIATRIC BLOOD & CANCER (2021)

Add to Collection

Article Hematology

Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1

M. Meaghan Granger et al.

Summary: BuMel ASCT following COG induction for high-risk neuroblastoma in children is well tolerated, with low rates of toxicity during consolidation and no deaths during this period. The 3-year event-free survival and overall survival rates are favorable for eligible patients.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

Add to Collection

Article Oncology

Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia

Kimberly P. Dunsmore et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear-medicine-based estimates of renal function

Peter C. Adamson et al.

PEDIATRIC BLOOD & CANCER (2019)

Add to Collection

Review Pediatrics

Chemotherapy and Supportive Care Agents as Essential Medicines for Children With Cancel

Yoram Unguru et al.

JAMA PEDIATRICS (2019)

Add to Collection

Review Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update

Mary Relling et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)

Add to Collection

Article Oncology

A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group

Meredith K. Chuk et al.

PEDIATRIC BLOOD & CANCER (2018)

Add to Collection

Article Oncology

Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force

Frank M. Balis et al.

PEDIATRIC BLOOD & CANCER (2017)

Add to Collection

Editorial Material Oncology

An Ethical Framework for Allocating Scarce Life-Saving Chemotherapy and Supportive Care Drugs for Childhood Cancer

Yoram Unguru et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)

Add to Collection

Editorial Material Oncology

An Ethical Framework for Allocating Scarce Life-Saving Chemotherapy and Supportive Care Drugs for Childhood Cancer

Yoram Unguru et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)

Add to Collection

Article Oncology

The Impact of Chemotherapy Shortages on COG and Local Clinical Trials: A Report From the Children's Oncology Group

Elizabeth G. Salazar et al.

PEDIATRIC BLOOD & CANCER (2015)

Add to Collection

Article Oncology

Templates of patient brochures for the preparation, administration and safe-handling of oral chemotherapy

Rivka Siden et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2014)

Add to Collection

© Peeref 2019-2024. All rights reserved.